5-Amino-1MQ

BioHacking Tides — Research Profile

5-Amino-1MQ

Overview:
5-Amino-1MQ is an experimental small molecule commonly discussed in research involving metabolism, body composition, and NNMT (nicotinamide N-methyltransferase).

Research Administration:
The reference describes both oral and subcutaneous administration.

Research Dosing Information:

• Oral: 50–150 mg daily; 50 mg capsules may be used 1–3 times daily with food.
• Subcutaneous: 1–10 mg daily. Some experimental protocols have explored higher amounts.

Reference Cycle:
6 weeks on, followed by 2 weeks off.

Research Notes:
Human clinical evidence remains limited, and protocols vary considerably between research sources.

 

9-ME-BC

BioHacking Tides — Research Profile

9-ME-BC

Overview:
9-ME-BC is an experimental research compound studied primarily in connection with neurological and cognitive research.

Research Administration:
Typically described as oral administration.

Research Dosing Information:

• 15–30 mg daily.
• The reference describes morning administration, with some protocols using a fasting period before the first meal.

Reference Cycle:
6 weeks on, followed by 2 weeks off.

Research Notes:
Human research data are limited.

 

Adamax

BioHacking Tides — Research Profile

Adamax

Overview:
Adamax is an experimental compound discussed in research involving neurological and cognitive pathways.

Research Administration:
Subcutaneous or intranasal administration.

Research Dosing Information:

• 100–500 mcg daily or as needed.
• The reference notes that experimental use may be adjusted as tolerance develops.

Reference Cycle:
Approximately 1 month on, 1 month off.

Research Notes:
Cycling recommendations vary because human data are limited.

 

AICAR

BioHacking Tides — Research Profile

AICAR

Overview:
AICAR is an experimental AMP-activated protein kinase (AMPK) activator studied extensively in metabolic and exercise-related research.

Research Administration:
Subcutaneous injection.

Research Dosing Information:
The reference describes experimental amounts of 10–25 mg per day, generally associated with pre-workout research.

Reference Cycle:
Approximately 2 weeks on, followed by 1–2 months off.

Research Notes:
Human data are limited. AICAR is primarily a research compound

 

Adipotide

BioHacking Tides — Research Profile

Adipotide

Overview:
Adipotide is an experimental peptide investigated for its effects on adipose tissue and metabolic pathways.

Research Administration:
Subcutaneous administration.

Research Dosing Information:
The reference describes 5 mcg/kg of body weight daily.

Reference Cycle:
Approximately 4 weeks on, followed by 4 weeks off.

Research Notes:
Research involving Adipotide has included significant safety considerations, particularly involving renal function.

 

AOD-9604

BioHacking Tides — Research Profile

AOD-9604

Overview:
AOD-9604 is a peptide fragment derived from human growth hormone that has been investigated primarily in relation to lipid metabolism and body composition.

Research Administration:
Subcutaneous administration.

Research Dosing Information:
The reference describes:

• Approximately 300–600 mcg once daily.
• Some protocols divide administration into morning and evening dosing.

Reconstitution Research Note:
Some research formulations use an acidic solution during preparation because of peptide stability considerations.

Reference Cycle:
Approximately 3 months on, followed by 1–2 months off.

 

ARA-290

BioHacking Tides — Research Profile

ARA-290

Overview:
ARA-290 is an experimental peptide derived from erythropoietin-related research and has been investigated for tissue-protective and metabolic effects.

Research Administration:
Subcutaneous injection.

Research Dosing Information:
Reference protocols include:

• Standard experimental range: 2–5 mg daily for 28–30 days.
• Maintenance research protocol: 3 mg three times per week for approximately 8 weeks.

Reference Cycle:
Equal breaks are described in the reference protocol.

 

BPC-157

BioHacking Tides — Research Profile

BPC-157

Overview:
BPC-157 is an experimental peptide widely studied in preclinical research involving tissue repair, gastrointestinal systems, vascular pathways, and inflammatory signaling.

Research Administration:
Subcutaneous, intramuscular, or oral administration has been described in research sources.

Research Dosing Information:
The supplied reference describes:

• Injection: approximately 500 mcg daily.
• Some research protocols divide the amount into two administrations.
• Oral: approximately 500–1,000 mcg as needed or daily.

Reference Cycle:
The reference recommends reassessment approximately every 8–12 weeks.

Research Notes:
Human clinical evidence remains limited.

 

Cagrilintide

BioHacking Tides — Research Profile

Cagrilintide

Overview:
Cagrilintide is a long-acting amylin analogue investigated for appetite regulation, food intake, and metabolic effects.

Research Administration:
Subcutaneous injection.

Reference Titration Schedule:

• Weeks 1–4: 0.25 mg
• Weeks 5–8: 0.5 mg
• Weeks 9–12: 1 mg
• Weeks 13–16: 1.7 mg
• Weeks 17+: 2.4 mg

Reference Cycle:
Continuous use is described in the supplied reference.

 

Cartalax

BioHacking Tides — Research Profile

Cartalax

Overview:
Cartalax is an experimental peptide discussed in research involving connective tissue and cartilage-related pathways.

Research Administration:
Subcutaneous, intramuscular, or oral administration.

Research Dosing Information:

• Injection: approximately 2 mg daily.
• Oral: approximately 21 mg capsules, 1–2 capsules 1–2 times daily.

Reference Cycle:
30 days on, followed by approximately 4 months off.

 

Cerebrolysin

BioHacking Tides — Research Profile

Cerebrolysin

Overview:
Cerebrolysin is a peptide-containing neurotrophic preparation investigated in neurological research.

Research Administration:
Intramuscular injection.

Research Amounts in Reference:

• Liquid ampoule: 1–5 mL daily.
• Lyophilized preparation: 6–30 mg daily.

Reference Cycle:
20–30 days, followed by approximately 3 months off.

 

CJC-1295 No DAC

BioHacking Tides — Research Profile

CJC-1295 No DAC

Overview:
CJC-1295 No DAC is an experimental growth-hormone-releasing peptide studied in connection with growth-hormone signaling.

Research Administration:
Subcutaneous injection.

Reference Dosing:

• 100–300 mcg.
• The reference describes 1–3 administrations daily.

Reference Cycle:
Approximately 8–12 weeks on, followed by 4 weeks off.

 

CJC-1295 With DAC

BioHacking Tides — Research Profile

CJC-1295 With DAC

Overview:
CJC-1295 with DAC is a long-acting growth-hormone-releasing peptide analogue.

Research Administration:
Subcutaneous injection.

Reference Dosing:

• Approximately 1–2 mg per week.
• The reference discusses dividing the weekly amount into smaller administrations.

Reference Cycle:
Approximately 8–12 weeks on, followed by 8 weeks off.

 

DSIP

BioHacking Tides — Research Profile

DSIP — Delta Sleep-Inducing Peptide

Overview:
DSIP is an experimental peptide investigated in connection with sleep, stress, and neuroendocrine signaling.

Research Administration:
Subcutaneous injection or nasal administration.

Reference Dosing:

• Subcutaneous: 100–300 mcg as needed.
• Nasal: 100–150 mcg per nostril as needed.

Reference Timing:
The supplied source describes administration approximately 2–3 hours before bedtime.

Reference Cycle:
4–8 weeks, followed by approximately 4 weeks off.

 

Eloralintide

BioHacking Tides — Research Profile

Eloralintide

Overview:
Eloralintide is an investigational metabolic peptide studied in connection with appetite regulation and body-weight management.

Research Administration:
Subcutaneous injection.

Reference Titration:

• Weeks 1–4: 1 mg
• Weeks 5–8: 3 mg
• Weeks 9–12: 6 mg
• Weeks 13+: 9 mg

Reference Cycle:
Continuous use is described.

 

Enclomiphene

BioHacking Tides — Research Profile

Enclomiphene

Overview:
Enclomiphene is the trans-isomer associated with clomiphene and has been investigated for effects on the hypothalamic-pituitary-gonadal axis.

Research Administration:
Oral.

Reference Research Applications:
The supplied material describes research protocols involving:

• Secondary hypogonadism.
• Post-cycle hormonal support.
• Male fertility.
• Female fertility.

Research Notes:
Dosing and duration vary substantially according to the research objective and hormonal measurements.

 

Epitalon

BioHacking Tides — Research Profile

Epitalon

Overview:
Epitalon is an experimental tetrapeptide investigated in aging, cellular, and longevity-related research.

Research Administration:
Subcutaneous, intramuscular, or oral administration.

Reference Research Protocols:
The supplied source describes several experimental approaches, including:

• Approximately 500 mcg daily for 10 days.
• Other protocols ranging from 500 mcg to 2.5 mg daily for approximately 20 days.

Reference Cycle:
Cycling intervals vary substantially between protocols.

 

FOXO4-DRI

BioHacking Tides — Research Profile

FOXO4-DRI

Overview:
FOXO4-DRI is an experimental peptide investigated in cellular-aging and senescence research.

Research Administration:
Subcutaneous injection.

Reference Dosing:
Approximately 2–5 mg every other day.

Reference Cycle:
3–5 doses, with experimental protocols repeated approximately quarterly.

Research Notes:
This is a highly experimental compound with limited human data.

 

GHK-Cu

BioHacking Tides — Research Profile

GHK-Cu

Overview:
GHK-Cu is a naturally occurring copper-binding peptide studied extensively in skin, connective tissue, wound-healing, and cellular signaling research.

Research Administration:
Subcutaneous administration is described in the supplied reference.

Reference Research Amount:
Approximately 2 mg daily.

Reference Cycle:
8–12 weeks on, followed by approximately 4 weeks off.

 

GLOW

BioHacking Tides — Research Profile

GLOW Peptide Blend

Overview:
GLOW is a combination research formulation containing GHK-Cu, BPC-157, and TB-500.

Reference Blend Ratios:

70 mg blend — 50/10/10

• 2 mg GHK-Cu
• 500 mcg BPC-157
• 500 mcg TB-500

50 mg blend — 35/10/5

• 1.75 mg GHK-Cu
• 500 mcg BPC-157
• 250 mcg TB-500

Reference Cycle:
8–12 weeks on, followed by approximately 4 weeks off.

 

Glutathione

BioHacking Tides — Research Profile

Glutathione

Overview:
Glutathione is a major intracellular antioxidant involved in cellular redox balance and detoxification pathways.

Research Administration:
Subcutaneous, intramuscular, or oral administration.

Reference Amounts:

• Injection: 100–200 mg daily or as needed.
• Oral: 250–500 mg as needed.

Reference Cycle:
4–8 weeks on, followed by approximately 4 weeks off.

 

Gonadorelin

BioHacking Tides — Research Profile

Gonadorelin

Overview:
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH) used in research involving reproductive hormone signaling.

Research Administration:
Subcutaneous injection.

Reference Research Applications:

• Post-cycle research: approximately 100 mcg daily for 2–3 weeks.
• Testosterone-support research: approximately 100–250 mcg three times weekly.

Reference Cycle:
Varies according to research objective.

 

HCG

BioHacking Tides — Research Profile

HCG — Human Chorionic Gonadotropin

Overview:
HCG is a gonadotropin investigated in reproductive and endocrine research.

Research Administration:
Subcutaneous injection.

Reference Research Applications:
The supplied material lists protocols associated with:

• Testosterone support.
• Post-cycle research.
• Male fertility.
• Female fertility.
• Ovarian restoration research.

Research Notes:
Protocols vary substantially depending on the research objective.

 

HGH

BioHacking Tides — Research Profile

HGH — Human Growth Hormone

Overview:
Human growth hormone is a peptide hormone involved in growth, metabolism, and tissue development.

Research Administration:
Subcutaneous injection.

Reference Research Ranges:

• Anti-aging/wellness research: 1–2 IU daily.
• Fat-loss research: 2–4 IU daily.
• Bodybuilding research: 4–10 IU daily.

Reference Cycle:
The source notes that cycling is not strictly required, although higher-dose research may incorporate periodic breaks.

 

IGF-1 LR3

BioHacking Tides — Research Profile

IGF-1 LR3

Overview:
IGF-1 LR3 is a long-acting analogue of insulin-like growth factor-1 investigated in growth and cellular signaling research.

Research Administration:
Subcutaneous or intramuscular injection.

Reference Research Amounts:

• Beginner: 25 mcg daily.
• Intermediate: 50 mcg daily.
• Advanced: 50–100 mcg daily.

Reference Cycle:
4–6 weeks with an approximately equal break.

 

Ipamorelin

BioHacking Tides — Research Profile

Ipamorelin

Overview:
Ipamorelin is a growth-hormone secretagogue investigated for its effects on growth-hormone release.

Research Administration:
Subcutaneous injection.

Reference Research Amount:
200–500 mcg, 1–3 times daily.

Reference Timing:
The supplied source describes research administration before sleep, in the morning, or before exercise.

Reference Cycle:
12–16 weeks on, followed by approximately 4 weeks off.

 

Ipamorelin / CJC-1295 No DAC

BioHacking Tides — Research Profile

Ipamorelin + CJC-1295 No DAC

Overview:
This combination pairs two growth-hormone secretagogues and is discussed in research involving growth-hormone signaling.

Research Administration:
Subcutaneous injection.

Reference Research Amount:
Approximately 200–600 mcg total per administration, with the source describing divided dosing.

Reference Cycle:
Approximately 8–12 weeks on, followed by 4 weeks off.

 

Kisspeptin

BioHacking Tides — Research Profile

Kisspeptin

Overview:
Kisspeptin is a neuropeptide involved in reproductive hormone signaling and regulation of the hypothalamic-pituitary-gonadal axis.

Research Administration:
Subcutaneous injection.

Reference Research Applications:
The supplied source describes experimental research involving:

• Testosterone support.
• Reproductive signaling.
• Fertility research.

Research Notes:
Dosing varies substantially according to the research objective.

 

KLOW

BioHacking Tides — Research Profile

KLOW Peptide Blend

Overview:
KLOW is a combination research formulation containing GHK-Cu, BPC-157, and TB-500.

Reference Blend:
80 mg blend:

• 2 mg GHK-Cu
• 400 mcg BPC-157
• 400 mcg TB-500

Reference Cycle:
8–12 weeks on, followed by approximately 4 weeks off.

 

KPV

BioHacking Tides — Research Profile

KPV

Overview:
KPV is a tripeptide derived from alpha-MSH and is investigated in research involving inflammatory and gastrointestinal pathways.

Research Administration:
Subcutaneous or oral.

Reference Research Amounts:

• Subcutaneous: 200–400 mcg daily.
• Oral: approximately 250 mcg twice daily.

Reference Cycle:
Cycling is not considered strictly required in the supplied reference; monthly reassessment is suggested.

 

L-Carnitine

BioHacking Tides — Research Profile

L-Carnitine

Overview:
L-Carnitine is involved in fatty-acid transport into mitochondria and is widely studied in metabolism and exercise research.

Research Administration:
Intramuscular or subcutaneous.

Reference Research Amounts:

• Pre-workout: 300–1,200 mg approximately 30 minutes before exercise.
• Maintenance: 300–600 mg daily.

Reference Cycle:
Continuous use is described as acceptable.

 

LIPO-C

BioHacking Tides — Research Profile

LIPO-C

Overview:
LIPO-C refers to injectable lipotropic formulations commonly investigated in metabolic and body-composition research.

Research Administration:
Intramuscular or subcutaneous.

Reference Research Amount:
1–3 mL, 1–3 times per week, depending on the formulation and research objective.

Reference Cycle:
Continuous use is described as acceptable.

 

LL-37

BioHacking Tides — Research Profile

LL-37

Overview:
LL-37 is an antimicrobial peptide investigated in immune, inflammatory, tissue-repair, and host-defense research.

Research Administration:
Subcutaneous or topical.

Reference Research Amounts:

• Immune-support research: 100–300 mcg, 1–2 times daily.
• Active-infection research: 300–500 mcg, 1–2 times daily.

Reference Cycle:
4–12 weeks on, followed by approximately 4 weeks off.

 

Mazdutide

BioHacking Tides — Research Profile

Mazdutide

Overview:
Mazdutide is an investigational metabolic peptide studied for effects involving glucose regulation, appetite, and body weight.

Research Administration:
Subcutaneous injection.

Reference Titration:

• Weeks 1–4: 1.5 mg
• Weeks 5–8: 3 mg
• Weeks 9–12: 4.5 mg
• Weeks 13–16: 6 mg
• Weeks 17–20: 7.5 mg
• Weeks 21+: 9 mg

Reference Cycle:
Continuous use is described.

 

Melanotan I

BioHacking Tides — Research Profile

Melanotan I

Overview:
Melanotan I is an experimental melanocortin analogue studied primarily in pigmentation research.

Research Administration:
Subcutaneous injection.

Reference Research Amount:
Approximately 200 mcg daily, with reduced-frequency maintenance protocols described after pigmentation develops.

Reference Maintenance:
Approximately 100 mcg twice weekly is cited in the supplied reference.

 

Melanotan II

BioHacking Tides — Research Profile

Melanotan II

Overview:
Melanotan II is an experimental melanocortin analogue investigated in pigmentation and melanocortin-receptor research.

Research Administration:
Subcutaneous injection.

Reference Research Amounts:

• Tanning research: approximately 200 mcg daily.
• Metabolic research: approximately 50 mcg daily.

Reference Cycle:
8–12 weeks on, followed by approximately 4 weeks off.

 

MGF

BioHacking Tides — Research Profile

MGF — Mechano Growth Factor

Overview:
MGF is a splice variant associated with IGF-1 signaling and is investigated in muscle and tissue-repair research.

Research Administration:
Intramuscular injection.

Reference Research Amount:
Approximately 100 mcg after exercise.

Reference Timing:
The supplied source describes administration approximately 30–60 minutes after training, targeted toward the trained muscle group.

Reference Cycle:
8 weeks on, followed by 2–4 weeks off.

 

MOTS-C

BioHacking Tides — Research Profile

MOTS-C

Overview:
MOTS-C is a mitochondria-derived peptide investigated in metabolic regulation, mitochondrial function, exercise physiology, and cellular stress research.

Research Administration:
Subcutaneous injection.

Reference Research Amount:
5 mg three times weekly.

Reference Cycle:
8 weeks on, followed by approximately 4 weeks off.

 

NAD+

BioHacking Tides — Research Profile

NAD+

Overview:
NAD+ (nicotinamide adenine dinucleotide) is a central cellular cofactor involved in energy metabolism, redox reactions, and cellular signaling.

Research Administration:
Subcutaneous, intramuscular, oral, or intranasal administration is described.

Reference Injectable Research Progression:

• Weeks 1–2: 25 mg twice weekly.
• Weeks 3–4: 50 mg twice weekly.
• Weeks 5–6: 50 mg three times weekly.
• Week 7+: increase according to research objective.

Reference Oral Amount:
250–1,000 mg daily as needed.

Reference Cycle:
Continuous use is described.

 

Oxytocin

BioHacking Tides — Research Profile

Oxytocin

Overview:
Oxytocin is a naturally occurring peptide hormone involved in social behavior, reproductive physiology, and neuroendocrine signaling.

Research Administration:
Subcutaneous or intranasal.

Reference Research Applications:

• Social/cognitive research: 40–75 mcg, 1–2 times daily.
• Intimacy-related research: 20–50 mcg before activity.
• Pain/inflammation research: 20–50 mcg, 1–3 times daily.

Reference Cycle:
Cycling data are limited.

 

PE-22-28

BioHacking Tides — Research Profile

PE-22-28

Overview:
PE-22-28 is an experimental peptide investigated in neurological and cognitive research.

Research Administration:
Subcutaneous or intranasal.

Reference Research Amount:
100–500 mcg daily or as needed.

Reference Cycle:
Human data are limited. The supplied reference describes approximately 1 month on and 1 month off for cognitive-peptide research.

 

Pinealon

BioHacking Tides — Research Profile

Pinealon

Overview:
Pinealon is an experimental peptide investigated in neurological, cellular-aging, and cognitive research.

Research Administration:
Subcutaneous or oral.

Reference Research Amounts:

• Subcutaneous: 0.5–1 mg daily.
• Acute-recovery research: 1–5 mg daily.
• Oral: 20 mg twice daily.

Reference Cycle:
10–20 days, with cycles repeated approximately every 3–6 months.

 

PT-141

BioHacking Tides — Research Profile

PT-141

Overview:
PT-141, also known as bremelanotide, is a melanocortin-receptor agonist investigated primarily in sexual-function research.

Research Administration:
Subcutaneous or intranasal.

Reference Research Amounts:
The supplied source lists different experimental amounts for male and female research.

Reference Cycle:
The source recommends not exceeding one administration within 24 hours or more than eight administrations per month.

 

RT3

BioHacking Tides — Research Profile

RT3

Overview:
Retatrutide is an investigational multi-receptor metabolic peptide targeting GLP-1, GIP, and glucagon pathways.

Research Administration:
Subcutaneous injection.

Reference Titration:

• Weeks 1–4: 2 mg
• Weeks 5–8: 4 mg
• Weeks 9–12: 4 mg
• Weeks 13–16: 4 mg
• Weeks 17–20: 4.5 mg
• Weeks 21+: 4.5 mg

Reference Note:
The supplied source notes that first-time GLP-1 research protocols may begin at a lower amount.

Reference Cycle:
Continuous use is described.

 

Selank

BioHacking Tides — Research Profile

Selank

Overview:
Selank is an experimental peptide investigated primarily in neurological, cognitive, anxiety-related, and stress-response research.

Research Administration:
Subcutaneous or intranasal.

Reference Research Amounts:

• Subcutaneous: 100–500 mcg daily or as needed.
• Intranasal: approximately 0.75–1 mg daily, commonly divided into 2–3 administrations.

Reference Cycle:
1 month on, followed by 1 month off.

 

Semaglutide

BioHacking Tides — Research Profile

Semaglutide

Overview:
Semaglutide is a GLP-1 receptor agonist studied extensively for effects on appetite regulation, glucose metabolism, and body weight.

Research Administration:
Subcutaneous injection.

Reference Titration:

• Weeks 1–4: 0.25 mg
• Weeks 5–8: 0.5 mg
• Weeks 9–12: 1 mg
• Weeks 13–16: 1.7 mg
• Weeks 17+: 2.4 mg

Reference Cycle:
Continuous use is described.

 

Semax

BioHacking Tides — Research Profile

Semax

Overview:
Semax is an experimental peptide studied primarily in neurological, cognitive, and neuroprotective research.

Research Administration:
Subcutaneous or intranasal.

Reference Research Amounts:

• Subcutaneous: 100–500 mcg daily or as needed.
• Intranasal: approximately 0.75–1 mg daily, commonly divided into 2–3 administrations.

Reference Cycle:
1 month on, followed by 1 month off.

Research Note:
The supplied reference recommends avoiding evening administration because of potential sleep disruption.

 

Sermorelin

BioHacking Tides — Research Profile

Sermorelin

Overview:
Sermorelin is a growth-hormone-releasing hormone analogue investigated for its ability to stimulate endogenous growth-hormone secretion.

Research Administration:
Subcutaneous injection.

Reference Research Amount:
200–500 mcg, 1–3 times daily.

Reference Timing:
The source describes research administration before sleep, in the morning, or before exercise.

Reference Cycle:
12–16 weeks on, followed by approximately 4 weeks off.

 

SS-31

BioHacking Tides — Research Profile

SS-31

Overview:
SS-31, also known as elamipretide, is a mitochondria-targeted experimental peptide investigated in mitochondrial function, cellular energy production, and oxidative-stress research.

Research Administration:
Subcutaneous injection.

Reference Research Information:
The supplied source notes that experimental dosing varies considerably by research protocol and that clinical research has evaluated substantially higher amounts.

Reference Research Protocol:

• MOTS-C/NAD+ preparation: 5 mg daily for 2–4 weeks.
• Maintenance: 500 mcg daily.

Reference Cycle:
Cycling data remain limited.

 

Survodutide

BioHacking Tides — Research Profile

Survodutide

Overview:
Survodutide is an investigational metabolic peptide studied for effects involving glucagon and GLP-1 receptor pathways.

Research Administration:
Subcutaneous injection.

Reference Titration:

• Weeks 1–4: 0.6 mg
• Weeks 5–8: 1.2 mg
• Weeks 9–12: 2.4 mg
• Weeks 13–16: 3.6 mg
• Weeks 17–20: 4.8 mg
• Weeks 21+: 6 mg

Reference Cycle:
Continuous use is described.

 

TB-500 / TB-4

BioHacking Tides — Research Profile

TB-500 / TB-4

Overview:
TB-500 refers to an experimental peptide associated with thymosin beta-4 research, particularly involving tissue repair and cellular migration.

Research Administration:
Subcutaneous or intramuscular injection.

Reference Research Amounts:

• Daily research protocol: approximately 500 mcg.
• Weekly research protocol: approximately 2 mg divided into 2–3 administrations.

Reference Cycle:
Strict cycling data are limited; reassessment every 8–12 weeks is suggested in the supplied source.

 

Teriparatide

BioHacking Tides — Research Profile

Teriparatide

Overview:
Teriparatide is a recombinant parathyroid-hormone fragment investigated for its effects on bone formation and skeletal remodeling.

Research Administration:
Subcutaneous injection.

Reference Research Applications:

• Fracture research: approximately 20 mcg daily for 8 weeks.
• Osteoporosis research: approximately 20 mcg daily for longer-term treatment protocols.

Research Notes:
Research duration varies according to the objective.

 

Tesamorelin

BioHacking Tides — Research Profile

Tesamorelin

Overview:
Tesamorelin is a growth-hormone-releasing hormone analogue studied particularly in relation to visceral adipose tissue and metabolic physiology.

Research Administration:
Subcutaneous injection.

Reference Research Amounts:

• Recovery research: 1 mg daily.
• Visceral-fat/body-composition research: 2 mg daily.

Reference Timing:
The supplied source describes administration before sleep or in the morning.

Reference Cycle:
The source describes long-term daily research protocols.

 

Thymosin Alpha-1

BioHacking Tides — Research Profile

Thymosin Alpha-1

Overview:
Thymosin Alpha-1 is an immunomodulatory peptide studied in immune-system and infectious-disease research.

Research Administration:
Subcutaneous injection.

Reference Research Applications:

• Immune support: 1–2 mg twice weekly.
• Illness-recovery research: 1–2 mg daily.
• Cancer-support research: 2 mg three times weekly.

Reference Cycle:
Cycling is not considered strictly required in the supplied reference.

 

Tirzepatide

BioHacking Tides — Research Profile

Tirzepatide

Overview:
Tirzepatide is a dual GIP/GLP-1 receptor agonist studied extensively in metabolic, glucose-control, appetite, and body-weight research.

Research Administration:
Subcutaneous injection.

Reference Titration:

• Weeks 1–4: 2.5 mg
• Weeks 5–8: 5 mg
• Weeks 9–12: 7.5 mg
• Weeks 13–16: 10 mg
• Weeks 17–20: 12.5 mg
• Weeks 21+: 15 mg

Reference Cycle:
Continuous use is described.

 

VIP

BioHacking Tides — Research Profile

VIP — Vasoactive Intestinal Peptide

Overview:
VIP is a naturally occurring neuropeptide involved in vascular, gastrointestinal, immune, and neurological signaling.

Research Administration:
Subcutaneous or intranasal.

Reference Research Amounts:

• Subcutaneous: 25–100 mcg, 1–3 times daily.
• Intranasal: 100–200 mcg, 1–3 times daily.

Reference Cycle:
Cycling is not considered strictly required; reassessment every 8–12 weeks is suggested.

 

Wolverine

BioHacking Tides — Research Profile

Wolverine — BPC-157 / TB-500

Overview:
Wolverine is a combination research protocol pairing BPC-157 and TB-500.

Research Administration:
Subcutaneous injection.

Reference Research Amounts:
Maintenance / Minor Injury:
0.5–1 mg total daily, described as approximately 250–500 mcg of each component.

Major Injury:
1–2 mg total daily, described as approximately 0.5–1 mg of each component.

Reference Cycle:
Strict cycling data are limited; reassessment every 8–12 weeks is suggested.